Meningioma pathophysiology: Difference between revisions

Jump to navigation Jump to search
Line 35: Line 35:
==Microscopic Pathology==
==Microscopic Pathology==
* On microscopic pathology, characteristic findings of meningioma include:
* On microscopic pathology, characteristic findings of meningioma include:
* The following immunohistochemistry profile can be used to support the diagnosis of meningioma:<ref name="ComminsAtkinson2007">{{cite journal|last1=Commins|first1=Deborah L.|last2=Atkinson|first2=Roscoe D.|last3=Burnett|first3=Margaret E.|title=Review of meningioma histopathology|journal=Neurosurgical Focus|volume=23|issue=4|year=2007|pages=E3|issn=1092-0684|doi=10.3171/FOC-07/10/E3}}</ref>
:* Positive for vimentin
:* Negative for cytokeratin
:* Weak or negative staining for S 100 protein
:* Focal membranous positivity for EMA


==References==
==References==

Revision as of 01:30, 18 April 2019

Meningioma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Meningioma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Interventions

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Meningioma pathophysiology On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Meningioma pathophysiology

All Images
X-rays
Echo and Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Meningioma pathophysiology

CDC on Meningioma pathophysiology

Meningioma pathophysiology in the news

Blogs on Meningioma pathophysiology

Directions to Hospitals Treating Meningioma

Risk calculators and risk factors for Meningioma pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Haytham Allaham, M.D. [2]

Overview

Meningioma arises from the arachnoid "cap" cells, which are normally involved in the protection of the central nervous system by forming a thick envelope of meninges around the brain and spinal cord.[1][2][3] The majority of meningiomas are benign. Development of meningioma is the result of multiple genetic mutations The majority of meningioma cases involve a deletion of the neurofibromatosis 2 gene located on chromosome 22. On gross pathology, a gray, well-circumscribed, dome-shaped mass is a characteristic finding of meningioma. On microscopic histopathological analysis, whorled appearance, calcification, and psammoma bodies are characteristic findings of meningioma.[4]

Pathogenesis

  • Meningiomas are the most common benign tumors of the brain. They are also the most common nonglial brain tumors.[5]
  • Meningioma arises from the arachnoid "cap" cells, which are normally involved in the protection of the central nervous system by forming a thick envelope of meninges around the brain and spinal cord.[6]
  • Meningiomas are commonly found in the base of the skull and perivenous sinuses due to the abundance of arachnoid cap cells in these sites. They are usually non-infilterative.[5]
  • The majority of meningiomas are benign (90%), about 6% are atypical, and 2% are malignant.[5]
  • Some meningiomas may be positive for progesterone receptors on histological examination. This can lead to increased tumor size and symptom burden during pregnancy and the luteal phase of the menstural cycle.[5]
  • Meningiomas may possess receptors for platelet derived growth factor, vascular endothelial growth factor (VEGF), glucocorticoid, and epidermal growth factor.[5]
  • Meningiomas can be found anywhere in the central nervous system, with its most frequent distribution as follows: parasagittal (20.8%), then convexity (15.2%), and tuberculum sellae (12.8%).[7]
  • The symptoms of meningioma can be flared by water retention, engorgement of blood vessels, and the presence of sex hormone receptors on tumor cells.[5]
  • A meningioma can be localized in the following areas: sphenoid ridge, olfactory groove, falx, lateral ventriculi, tentorium, the middle fossa, the orbit, the spinal channel, the Sylvian fissure, extracalvarial, multiple localization, the pontocerebral angle, the sphenoidal plane, and the foramen magnum.[7]
  • The characteristics of a meningioma can be determined based on histopathological variables like tumor gradient, histological subtype, proliferative index, and invasiveness of a tumor to the brain.[7]
  • The characterization of a meningioma being malignant is based on one or more of the following criteria: brain invasion, frank anaplasia, and distant metastasis[8]

Genetics

Genes involved in the pathogenesis of meningioma include:[9][8]

  • Neurofibromatosis 2 (NF2) gene on chromosome 22
  • TRAF7
  • AKT1
  • KLF4
  • SMO
  • PIK3CA

Gross Pathology

  • On gross pathology, a gray, well-circumscribed, dome-shaped mass is a characteristic finding of meningioma.[1]


Gross pathology: Cut surface of a resected meningioma[10]

Microscopic Pathology

  • On microscopic pathology, characteristic findings of meningioma include:


  • The following immunohistochemistry profile can be used to support the diagnosis of meningioma:[8]
  • Positive for vimentin
  • Negative for cytokeratin
  • Weak or negative staining for S 100 protein
  • Focal membranous positivity for EMA

References

  1. 1.0 1.1 Meningioma. Wikipedia(2015) https://en.wikipedia.org/wiki/Meningioma#cite_note-pmid7731706-9 Accessed on September, 25 2015
  2. Meningioma. Canadian Cancer Society http://www.cancer.ca/en/cancer-information/cancer-type/brain-spinal/brain-and-spinal-tumours/meningioma/?region=mb September, 25 2015
  3. Meningeoma. Radiopaedia(2015)http://radiopaedia.org/articles/meningioma Accessed on September, 25 2015
  4. Meningioma. Libre Pathology(2015) http://librepathology.org/wiki/index.php/Meningioma#Quick_overview accessed on September, 25 2015
  5. 5.0 5.1 5.2 5.3 5.4 5.5 Gurcay AG, Bozkurt I, Senturk S, Kazanci A, Gurcan O, Turkoglu OF; et al. (2018). "Diagnosis, Treatment, and Management Strategy of Meningioma during Pregnancy". Asian J Neurosurg. 13 (1): 86–89. doi:10.4103/1793-5482.181115. PMC 5820904. PMID 29492130.
  6. Wiemels J, Wrensch M, Claus EB (2010) Epidemiology and etiology of meningioma. J Neurooncol 99 (3):307-14. DOI:10.1007/s11060-010-0386-3 PMID: 20821343
  7. 7.0 7.1 7.2 Sumkovski R, Micunovic M, Kocevski I, Ilievski B, Petrov I (2019). "Surgical Treatment of Meningiomas - Outcome Associated With Type of Resection, Recurrence, Karnofsky Performance Score, Mitotic Count". Open Access Maced J Med Sci. 7 (1): 56–64. doi:10.3889/oamjms.2018.503. PMC 6352459. PMID 30740161.
  8. 8.0 8.1 8.2 Commins, Deborah L.; Atkinson, Roscoe D.; Burnett, Margaret E. (2007). "Review of meningioma histopathology". Neurosurgical Focus. 23 (4): E3. doi:10.3171/FOC-07/10/E3. ISSN 1092-0684.
  9. Yuzawa S, Nishihara H, Tanaka S (2016). "Genetic landscape of meningioma". Brain Tumor Pathol. 33 (4): 237–247. doi:10.1007/s10014-016-0271-7. PMID 27624470.
  10. Image courtesy of Dr Dharam Ramnani Radiopaedia(original file "here"). Creative Commons BY-SA-NC


Template:WikiDoc Sources